hwkn-20220518
0000046250FALSE00000462502022-05-182022-05-18

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 8-K
 
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) May 18, 2022
  
Hawkins, Inc.
(Exact name of registrant as specified in its charter)
 
Minnesota 0-7647 41-0771293
(State of Incorporation) (Commission File Number) (IRS Employer Identification No.)
2381 Rosegate,Roseville,MN55113
(Address of Principal Executive Offices)(Zip Code)

Registrant’s Telephone Number, Including Area Code (612331-6910
  
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $.01 per share
HWKN
Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act (17 CFR 230.405) or Rule 12b-2 of the Exchange Act (17 CFR 240.12b 2).
Emerging growth company ¨
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨




Item 2.02. Results of Operations and Financial Condition.
On May 18, 2022, Hawkins, Inc. issued a press release announcing financial results for its fourth quarter and fiscal year ended April 3, 2022. A copy of the press release issued by the Registrant is furnished herewith as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.
(d)Exhibits.
Exhibit No.  Description  Method of Filing
  
Press Release, dated May 18, 2022, announcing financial results of Hawkins, Inc. for its fourth quarter and fiscal year ended April 3, 2022.
  Filed Electronically
104 Cover Page Interactive Data File (embedded within the inline XBRL document)Filed Electronically




SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 HAWKINS, INC.
Date: May 18, 2022
 By: /s/ Jeffrey P. Oldenkamp
  Jeffrey P. Oldenkamp
  
Executive Vice President and Chief Financial Officer


Document

Exhibit 99.1
May 18, 2022
Hawkins, Inc.
2381 Rosegate
Roseville, MN 55113

Hawkins, Inc. Reports
Fourth Quarter and Fiscal Year 2022 Results

ROSEVILLE, Minn., May 18, 2022 – Hawkins, Inc. (Nasdaq: HWKN), a leading specialty chemical and ingredients company, today announced fourth quarter and full-year results for its fiscal year ended April 3, 2022.

Fourth Quarter Fiscal Year 2022 Highlights:

Record quarterly sales in the fourth quarter of $223.0 million, a 37% year-over-year increase.
Gross profit of $36.3 million for the quarter, a 14% increase over the same period of the prior year, while absorbing $8.2 million in incremental LIFO expense in the quarter.
Record fourth quarter diluted earnings per share (EPS) of $0.50, which was 16% higher than the same period of the prior year.
Adjusted earnings before interest, taxes, depreciation, and amortization (adjusted EBITDA), a non-GAAP measure, of $22.3 million, an 11% increase over the same period of the prior year.

Full-Year Fiscal Year 2022 Highlights:

Record annual sales of $774.5 million for fiscal 2022, a 30% year-over-year increase.
Record gross profit of $146.5 million for the year, an 18% increase over the prior year, which contributed to a 27% year-over-year increase in operating income.
Record diluted EPS of $2.44, which was $0.51, or 26%, higher than fiscal 2021.
Record adjusted EBITDA, a non-GAAP measure, of $99.7 million, an increase of 19% over fiscal 2021.
Full year net income increased 26% over the prior year.
Paid cash dividends of $0.5225 per share for the year, representing an increase of 11% over the prior year. This marks the 37th consecutive year of paying a dividend.
Completed three acquisitions during the year.
Ended the year with net debt of $123 million and a leverage ratio of 1.25x.
Issued our second annual ESG report, with a goal of being carbon neutral by 2040.

Executive Commentary – Patrick H. Hawkins, Chief Executive Officer and President:

“For the third year in a row we generated record operating income, net income, diluted EPS, and adjusted EBITDA, while achieving record sales of $775 million and adjusted EBITDA of $100 million in fiscal 2022. This strong three-year run has delivered compounded EPS growth of 29% over that timeframe. This performance is the result of the hard work by our many employees, our innovative solutions to the opportunities that have arisen, as well as outstanding relationships with our customers and suppliers, which we never take for granted. In fiscal 2022, we made significant investments in added personnel and other resources that we expect to leverage in the coming years to grow the business.”

Mr. Hawkins, continued, “We had 30% revenue growth for the year, which included the results of our six acquisitions over the past 18 months and a 27% organic growth from our existing business, with all three reporting segments growing over the prior year. Sales in our Industrial segment grew 42% over the prior year, with more than half of the year-over-year growth coming from our higher-margin business in agricultural, pharmaceutical and food ingredient product lines. Our margins continued to be impacted by macro-economic pressures, including inflation and global supply chain disruptions. Despite these headwinds, we generated $71 million of operating income, an increase of $15 million over the prior year and included a LIFO impact of nearly $16 million in fiscal 2022 due to unprecedented rising raw material costs. We look forward to continuing our topline growth into fiscal 2023 and managing our cost structure to drive our bottom line.”





Fourth Quarter and Fiscal Year Financial Highlights:

NET INCOME

For the fourth quarter of fiscal 2022, the Company reported net income of $10.6 million, or $0.50 per diluted share, compared to net income for the fourth quarter of fiscal 2021 of $9.1 million, or $0.43 per diluted share.

For the full year, the Company reported record net income of $51.5 million, or $2.44 per diluted share, compared to net income for fiscal 2021 of $41.0 million, or $1.93 per diluted share.

REVENUE

For the fourth quarter of fiscal 2022, sales were $223.0 million, an increase of $60.0 million, or 37%, from sales of $163.0 million a year ago. Industrial segment sales increased $41.0 million, or 54%, to $117.4 million for the current quarter, as compared to $76.3 million for the same period a year ago. We estimate the impact of the extra week in the quarter to be approximately $10.0 million in additional sales in the Industrial segment. In addition, the increase in sales was driven by increased selling prices on many of our products driven by higher costs on many of our raw materials, as well as increased sales volumes of our bulk and our manufactured, blended and repackaged products. Water Treatment segment sales increased $18.5 million, or 45%, to $60.0 million for the current quarter, as compared to $41.5 million for the same period a year ago. We estimate the impact of the extra week in the quarter to be approximately $4.0 million in additional sales in the Water Treatment segment. In addition, sales increased as a result of increased demand for our products as well as the added sales from acquisitions. Health and Nutrition segment sales increased $0.4 million, or 1%, to $45.6 million for the current quarter, as compared to $45.2 million for the same period a year ago. We estimate the impact of the extra week in the quarter to be approximately $3.5 million in additional sales in the Health and Nutrition segment, which was partially offset by the normalizing of demand for our manufactured products when compared to the temporary COVID-driven increase in demand these products experienced in the prior year.

For fiscal 2022, Industrial segment sales were $386.9 million, an increase of 42% from fiscal 2021 sales of $273.4 million. Water Treatment segment sales were $228.1 million for the year, an increase of 34% over last year’s sales of $170.0 million. Sales for our Health and Nutrition segment were $159.5 million in fiscal 2022, an increase of 4% from fiscal 2021 sales of $153.5 million. We estimate the total impact of the extra week in the year to be approximately $17.5 million.

GROSS PROFIT

Company-wide gross profit for fiscal 2022 increased $22.8 million, or 18%, to $146.5 million, or 19% of sales, from $123.8 million, or 21% of sales, for the same period of the prior year. During fiscal 2022, the LIFO reserve increased, and gross profits decreased, by $15.8 million, primarily due to rising input costs. In fiscal 2021, the LIFO reserve decreased, and gross profits increased, by $0.1 million. We estimated the impact of the 53rd week in fiscal 2022 to be approximately $3.6 million in additional gross profit.

Gross profit for the Industrial segment increased $16.3 million, or 38%, to $59.6 million, or 15% of sales, for fiscal 2022, from $43.3 million, or 16% of sales, for fiscal 2021. During fiscal 2022, the LIFO reserve increased, and gross profits decreased, by $10.4 million, primarily due to rising raw material costs. In fiscal 2021, the LIFO reserve decreased, and gross profits increased, by $0.2 million. We estimated the impact of the 53rd week in fiscal 2022 to be approximately $1.9 million in additional gross profit in the Industrial segment. In addition, gross profit increased as a result of the increase in sales, partially offset by the negative impact as a result of the increase in LIFO reserve.

Gross profit for the Water Treatment segment increased $7.8 million, or 17%, to $54.6 million, or 24% of sales, for fiscal 2022, from $46.8 million, or 28% of sales, for fiscal 2021. During fiscal 2022, the LIFO reserve increased, and gross profits decreased, by $5.4 million, primarily due to rising raw material costs. During fiscal 2021, the LIFO reserve increased, and gross profit decreased, by $0.1 million. We estimated the impact of the 53rd week in fiscal 2022 to be approximately $1.0 million in additional gross profit in the Water Treatment segment. In addition, gross profit increased as a result of the increase in sales.

Gross profit for the Health and Nutrition segment decreased $1.3 million, or 4%, to $32.3 million, or 20% of sales, for fiscal 2022, from $33.6 million, or 22% of sales, for fiscal 2021. We estimated the impact of the 53rd week in fiscal 2022 to be approximately $0.7 million in additional gross profit in the Health and Nutrition segment. This increase was more than offset by a decrease in gross profit resulting from a decline in sales of our manufactured products which generally have higher per-unit margins than our specialty distributed products.





SELLING, GENERAL AND ADMINISTRATIVE EXPENSES

Selling, general and administrative ("SG&A") expenses increased to $75.3 million, or 10% of sales, for fiscal 2022 from $67.9 million, or 11% of sales, for fiscal 2021. We estimated the impact of the 53rd week in fiscal 2022 to be approximately $1.0 million in additional SG&A expense. In addition, expenses increased in part due to the added costs from the acquired businesses in the Water Treatment segment, an increase in variable incentive compensation, increased costs due to added personnel and other resources as we invest to grow the business, and normalization of travel and other variable expenses to pre-COVID levels.

ADJUSTED EBITDA

Adjusted EBITDA, a non-GAAP financial measure, is an important performance indicator and a key compliance measure under the terms of our credit agreement. An explanation of the computation of adjusted EBITDA is presented below. Adjusted EBITDA for the three months ended April 3, 2022 was $22.3 million, an increase of $2.2 million, or 11%, from adjusted EBITDA of $20.1 million for the same period in the prior year. Full-year adjusted EBITDA was $99.7 million, an increase of $15.8 million, or 19%, from adjusted EBITDA of $83.9 million for fiscal 2021. The increase was due to the impact of improved gross profits discussed above.

Our effective income tax rate was relatively flat at approximately 26.5% for both fiscal 2022 and 2021.

About Hawkins, Inc.

Hawkins, Inc. was founded in 1938 and is a leading specialty chemical and ingredients company that formulates, distributes, blends and manufactures products for its Industrial, Water Treatment, and Health & Nutrition customers. Headquartered in Roseville, Minnesota, and with 49 facilities in 24 states, the Company creates value for its customers through superb customer service and support, quality products and personalized applications. Hawkins, Inc. generated $775 million of revenue in fiscal 2022 and has approximately 800 employees. For more information, including registering to receive email alerts, please visit www.hawkinsinc.com/investors.

Reconciliation of Non-GAAP Financial Measures
We report our consolidated financial results in accordance with U.S. generally accepted accounting principles (GAAP). To assist investors in understanding our financial performance between periods, we have provided certain financial measures not computed according to GAAP, including adjusted EBITDA. This non-GAAP financial measure is not meant to be considered in isolation or as a substitute for comparable GAAP measures. The method we use to produce non-GAAP results is not computed according to GAAP and may differ from the methods used by other companies.
Management uses this non-GAAP financial measure internally to understand, manage and evaluate our business and to make operating decisions. Management believes that this non-GAAP financial measure reflects an additional way of viewing aspects of our operations that, when viewed with our GAAP results, provides a more complete understanding of the factors and trends affecting our financial condition and results of operations.
We define adjusted EBITDA as GAAP net income adjusted for the impact of the following: net interest expense resulting from our net borrowing position; income tax expense; non-cash expenses including amortization of intangibles, depreciation, and charges for the employee stock purchase plan and restricted stock grants; and non-recurring items of income or expense, if applicable.



Adjusted EBITDAThree Months EndedFiscal Year Ended
(In thousands)April 3, 2022March 28, 2021April 3, 2022March 28, 2021
Net income (GAAP)$10,577 $9,081 $51,542 $40,980 
Interest expense409 366 1,404 1,467 
Income tax expense3,864 3,586 18,437 14,871 
Amortization of intangibles1,758 1,602 6,462 5,839 
Depreciation expense4,512 4,331 17,667 16,829 
Non-cash compensation expense1,111 1,040 3,818 3,343 
Non-recurring acquisition expense73 54 369 562 
Adjusted EBITDA$22,304 $20,060 $99,699 $83,891 






 
HAWKINS, INC.
CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)
(In thousands, except share and per-share data)
Three Months EndedFiscal Year Ended
 April 3, 2022March 28, 2021April 3, 2022March 28, 2021
(unaudited)
Sales$222,973 $162,971 $774,541 $596,871 
Cost of sales(186,654)(131,221)(628,021)(473,109)
Gross profit36,319 31,750 146,520 123,762 
Selling, general and administrative expenses(21,110)(18,875)(75,326)(67,884)
Operating income15,209 12,875 71,194 55,878 
Interest expense, net(409)(366)(1,404)(1,467)
Other income (expense)(359)158 189 1,440 
Income before income taxes14,441 12,667 69,979 55,851 
Income tax expense(3,864)(3,586)(18,437)(14,871)
Net income$10,577 $9,081 $51,542 $40,980 
Weighted average number of shares outstanding-basic20,887,460 20,968,248 20,947,234 21,024,344 
Weighted average number of shares outstanding-diluted21,078,783 21,194,455 21,135,258 21,260,296 
Basic earnings per share$0.51 $0.43 $2.46 $1.95 
Diluted earnings per share $0.50 $0.43 $2.44 $1.93 

 






HAWKINS, INC.
CONSOLIDATED BALANCE SHEETS (UNAUDITED)
(In thousands, except share and per-share data)
April 3, 2022March 28, 2021
ASSETS
CURRENT ASSETS:
Cash and cash equivalents$3,496 $2,998 
Trade accounts receivables, net122,826 90,603 
Inventories94,985 63,864 
Prepaid expenses and other current assets6,431 5,542 
Total current assets227,738 163,007 
PROPERTY, PLANT, AND EQUIPMENT:
Land16,640 15,235 
Buildings and improvements118,369 120,410 
Machinery and equipment114,763 109,353 
Transportation equipment43,968 37,646 
Office furniture and equipment10,315 17,760 
304,055 300,404 
Less accumulated depreciation142,209 155,792 
Net property, plant, and equipment161,846 144,612 
OTHER ASSETS:
Right-of-use assets10,606 11,630 
Goodwill77,401 70,720 
Intangible assets, net80,193 76,368 
Deferred compensation plan asset6,783 5,726 
Other2,761 487 
Total other assets177,744 164,931 
Total assets$567,328 $472,550 
LIABILITIES AND SHAREHOLDERS’ EQUITY
CURRENT LIABILITIES:
Accounts payable — trade$66,693 $37,313 
Accrued payroll and employee benefits19,034 18,048 
Current portion of long-term debt9,913 9,907 
Short-term lease liability1,657 1,587 
Container deposits1,558 1,452 
Other current liabilities2,611 2,155 
Total current liabilities101,466 70,462 
LONG-TERM DEBT, LESS CURRENT PORTION115,644 88,845 
LONG-TERM LEASE LIABILITY9,143 10,231 
PENSION WITHDRAWAL LIABILITY4,276 4,631 
DEFERRED COMPENSATION LIABILITY8,402 7,322 
DEFERRED INCOME TAXES23,422 24,445 
OTHER LONG-TERM LIABILITIES2,374 1,368 
Total liabilities264,727 207,304 
COMMITMENTS AND CONTINGENCIES— — 
SHAREHOLDERS’ EQUITY:
Common shares; authorized: 60,000,000 shares of $0.01 par value; 20,889,777 and 20,969,746 shares issued and outstanding for 2022 and 2021, respectively209 210 
Additional paid-in capital46,717 51,138 
Retained earnings254,384 213,898 
Accumulated other comprehensive income1,291 — 
Total shareholders’ equity302,601 265,246 
Total liabilities and shareholders’ equity$567,328 $472,550 




HAWKINS, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
(In thousands)
  
Fiscal Year Ended
 April 3, 2022March 28, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income$51,542 $40,980 
Reconciliation to cash flows:
Depreciation and amortization24,129 22,669 
Operating leases1,899 1,896 
Gain on deferred compensation assets(189)(1,440)
Deferred income taxes(1,501)(689)
Stock compensation expense3,818 3,343 
Other545 203 
Changes in operating accounts (using) providing cash, net of acquisitions:
Trade receivables(30,526)(21,323)
Inventories(30,034)(7,960)
Accounts payable25,138 2,551 
Accrued liabilities2,723 7,554 
Lease liabilities(1,907)(1,837)
Income taxes214 (235)
Other(3,014)(1,919)
Net cash provided by operating activities42,837 43,793 
CASH FLOWS FROM INVESTING ACTIVITIES:
Additions to property, plant, and equipment(28,512)(20,794)
Acquisitions(21,546)(51,000)
Other302 362 
Net cash used in investing activities(49,756)(71,432)
CASH FLOWS FROM FINANCING ACTIVITIES:
Cash dividends paid(11,056)(10,029)
New shares issued1,772 1,583 
Shares surrendered for payroll taxes(1,467)(54)
Shares repurchased(8,545)(4,140)
Payments for debt issuance costs(287)— 
Payments on senior secured revolving loan(15,000)(37,000)
Borrowings on senior secured revolving loan42,000 76,000 
Net cash provided by financing activities7,417 26,360 
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS498 (1,279)
CASH AND CASH EQUIVALENTS - beginning of year2,998 4,277 
CASH AND CASH EQUIVALENTS - end of year$3,496 $2,998 
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION-
Cash paid during the year for income taxes$19,726 $15,783 
Cash paid for interest1,197 1,288 
Noncash investing activities - Capital expenditures in accounts payable3,733 626 




HAWKINS, INC.
REPORTABLE SEGMENTS (UNAUDITED)
(In thousands)

IndustrialWater
Treatment
Health and NutritionTotal
   
Fiscal Year Ended April 3, 2022:
Sales$386,938 $228,133 $159,470 $774,541 
Gross profit59,606 54,571 32,343 146,520 
Selling, general, and administrative expenses28,127 31,357 15,842 75,326 
Operating income31,479 23,214 16,501 71,194 
Fiscal Year Ended March 28, 2021:
Sales$273,361 $170,004 $153,506 $596,871 
Gross profit43,337 46,793 33,632 123,762 
Selling, general, and administrative expenses27,033 24,453 16,398 67,884 
Operating income (loss)16,304 22,340 17,234 55,878 




Forward-Looking Statements. Various remarks in this press release constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include those relating to consumer demand for products containing our ingredients and the impacts of those demands, expectations for results in our business segments and the timing of our filings with the Securities and Exchange Commission. These statements are not historical facts, but rather are based on our current expectations, estimates and projections, and our beliefs and assumptions. Forward-looking statements may be identified by terms, including “anticipate,” “believe,” “can,” “could,” “expect,” “intend,” “may,” “predict,” “should,” or “will” or the negative of these terms or other comparable terms. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors, some of which are beyond our control and are difficult to predict. Actual results may vary materially from those contained in forward looking statements based on a number of factors, including, but not limited to, changes in regulation, availability of technological improvements, the impact and severity of the COVID-19 outbreak, changes in the labor markets, our available cash for investments, changes in competition and price pressures, changes in demand and customer requirements or processes for our products, availability of product and disruptions to supplies, interruptions in production resulting from hazards, transportation limitations or other extraordinary events outside our control that may negatively impact our business or the supply chains in which we participate, changes in imported products and tariff levels, the availability of products and the prices at which they are available, the acceptance of new products by our customers and the timing of any such acceptance, and changes in product supplies. Additional information concerning potential factors that could affect future financial results is included in our Annual Report on Form 10-K for the fiscal year ended March 28, 2021, as updated from time to time in amendments and subsequent reports filed with the SEC. Investors should take such risks into account when making investment decisions. Shareholders and other readers are cautioned not to place undue reliance on forward-looking statements, which reflect our management’s view only as of the date hereof. We do not undertake any obligation to update any forward-looking statements.

Contacts:    Jeffrey P. Oldenkamp
Executive Vice President and Chief Financial Officer
612/331-6910
ir@HawkinsInc.com